Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

malignant glioma - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

malignant glioma

MONDO:0100342

Also known as:gliomaneuroglial tumorneuroglial tumour

Find Clinical TrialsTrials

Overview

A grade III or grade IV glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma.

Treatments4 FDA approved, newest 2025

Clinical Trials186 registered · 47 recruiting

Diagnosis

Biomarker and diagnostic research for malignant glioma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

4 FDA-approved treatments are available for malignant glioma, including CARMUSTINE (GLIADEL, approved 1996), DORDAVIPRONE (MODEYSO, approved 2025), and TOVORAFENIB (OJEMDA, approved 2024). An additional 113 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

186 clinical trials registered, 47 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 3 PHASE4, 2 PHASE3, 31 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06305910](https://clinicaltrials.gov/study/NCT06305910)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of GLIADEL for managing malignant glioma?
→Are any of the 186 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Laboratory research	116	34%
Research summaries	93	28%
Testing and diagnosis research	35	10%
Disease patterns and progression	31	9%
New treatment approaches	28	8%
Clinical study results	20	6%
Patient case studies	10	3%
Other research	5	1%

Kisho

malignant glioma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

malignant glioma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications